No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KNSA Kiniksa Pharmaceuticals
- 18.200
- -0.330-1.78%
Close Jun 18 16:00 ET
1.29BMarket Cap140.00P/E (TTM)
18.630High18.040Low481.11KVolume18.520Open18.530Pre Close8.78MTurnover3.42%Turnover Ratio91.00P/E (Static)70.94MShares22.09052wk High2.99P/B255.72MFloat Cap13.56052wk Low--Dividend TTM14.05MShs Float32.880Historical High--Div YieldTTM3.18%Amplitude5.010Historical Low18.240Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pulls Back 3.9% This Week, but Still Delivers Shareholders Decent 6.4% CAGR Over 5 Years
The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up more than the market average. But Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) ha
Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative
PDF Version – Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –– American Heart Association to work with champions at 15 healthcare sites to implement i
Express News | Kiniksa Pharmaceuticals - Expects Redomiciliation To Take Effect On Or Around June 27, 2024; Supreme Court Of Bermuda Issued An Order Sanctioning Scheme Of Arrangement Between Company And Its Shareholders
Express News | Kiniksa Pharmaceuticals Ltd - Supreme Court of Bermuda Issued an Order Sanctioning Scheme of Arrangement Between Company and Its Shareholders
Express News | Kiniksa Pharmaceuticals Ltd - Expects Redomiciliation to Take Effect on or Around June 27, 2024
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
PDF Version HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman
Comments
The share price rise is a fair reaction to the company's revenue growth. More gains could follow if the trend continues. Yet, consider the company's profitability and cash flow before investing.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Delivers Shareholders Respectable 66% Return Over 1 Year, Surging 4.7% in the Last Week AloneKiniksa Pharmaceuticals' low P/S ratio may be due to its forecast growth being lower than the industry. Shareholders accept this, conceding future revenue probably won't surprise positively. It's hard to see the share price rising strongly soon under these circumstances.
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2 ...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2 ...
36
6
Kiniksa Pharmaceuticals' growing cash burn is offset by substantial cash reserves & signs of business growth. The firm can issue shares or borrow cheaply to fund further growth.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg